Prior to commencing accrual, each study site will be required to self-identify their site as a site with external beam radiation therapy (EBRT+) or without (EBRT-) the capacity to provide radiation therapy as specified in the durvalumab + EBRT arm. The radiation therapy status of each site will remain fixed throughout the course of the trial.